about
Successful treatment of severe gastrointestinal bleeding secondary to Crohn disease with recombinant factor VIIa.Association between the HTR2C rs1414334 C/G gene polymorphism and the development of the metabolic syndrome in patients treated with atypical antipsychotics.Filgrastim use in the emergency department of a Spanish general hospital.Treatment of hyponatremia induced by the syndrome of Inappropriate antidiuretic hormone secretion: a multidisciplinary spanish algorithm.Dose modification of anti-TNF in rheumatoid arthritis and estimated economical impact: a review of observational studies.Pharmacokinetic monitoring of chronic treatment with digoxin from Primary Health Care.Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism.Ciprofloxacin, but not levofloxacin, affects cyclosporine blood levels in a patient with pure red blood cell aplasia.Using clopidogrel in non-ST-segment elevation acute coronary syndrome patients: a cost-utility analysis in Spain.Acenocoumarol-induced Henoch-Schönlein purpura.Acute seizures due to a probable interaction between valproic acid and meropenem.Optic neuritis with concurrent etanercept and isoniazid therapy.[Fatal cerebral malaria caused by Plasmodium falciparum after treatment with exchange transfusion][The treament of hyponatremia secundary to the syndrome of inappropriate antidiuretic hormone secretion].Chemical stability of ondansetron hydrochloride with other drugs in admixtures via parenteral; a review.[Subcutaneous drug administration in palliative care].Pure red cell aplasia associated with dapsone therapy.Use of recombinant factor VIIa for life-threatening bleeding in a patient with severe necrotizing pancreatitis.Relationship between the rs1414334 C/G polymorphism in the HTR2C gene and smoking in patients treated with atypical antipsychotics.Development and validation of a guide for the continuity of care in perioperative medication managementExtracorporeal removal of vancomycin by plasmapheresis[Assessment of quality as perceived by users of an outpatient pharmaceutical care unit][Bases of the pharmaceutical care in Hospital Pharmacy][Pharmaceutical care in renal insufficiency inpatients][Enoxaparin dosage in extreme obesity by monitoring anti-Xa factor]Biopharmaceutical optimization in neglected diseases for paediatric patients by applying the provisional paediatric biopharmaceutical classification systemAdequacy of Parenteral Nutrition in Preterm Infants According to Current Recommendations: A Study in A Spanish HospitalAvailability of Authorizations from EMA and FDA for Age-Appropriate Medicines Contained in the WHO Essential Medicines List for Children 2019Stability and compatibility of ondansetron with haloperidol in parenteral admixtures
P50
Q36859806-FEE646E9-F12F-409A-9785-72D7CCF26D34Q37087294-48F89617-4068-4DC5-91BF-B142131F2A09Q38203978-DA26B643-77A2-413B-A517-69745F24AEBDQ38230892-39D582FB-C2A6-4C30-8F51-F0749147D951Q38306139-8857B098-1F1C-49FF-A552-F3A8C89F8A03Q38690690-26BED9C4-6377-40F5-B6C2-1901B8E1C33BQ39795153-73BBCED5-BD27-429B-A180-9BD3BA891177Q40498219-1AFE72E9-D75A-4733-B5AE-C06A96A5DB13Q44726460-BB252A02-FAF8-41AE-A8E1-727410AE634CQ44741590-72C19F19-738B-4BFB-8066-57E958397F8CQ45258188-7E080890-E876-4037-9CFD-DDE160711676Q46786771-2053E707-99B7-4F51-9120-DC5176CA2A80Q47870297-DC5A9CEC-F06A-4E85-BBBA-669A5794FBDBQ48918892-F40A34CA-D40E-471A-92C5-FECE5DBABB39Q50027530-C323B4E9-460B-49FC-8F8B-E0F6F901FE04Q50047449-CB8ED878-4624-4BF1-845C-C5EFC24D5A20Q50767243-BE4C64C2-F2FB-484B-97D3-CF74AF5AB5E1Q53741300-399B5B04-05A2-46EE-9379-5EB3794944DCQ54423382-251C9F0A-2FB5-4043-9B99-0B7CB3E1EAB1Q58701773-4F9FDD6F-E312-4848-963A-8A30B2C86A11Q79389951-8B077557-2C20-4B2F-B443-B575630F60B3Q79779537-73FB1776-238B-47A1-A9B9-4C612483136DQ79779548-C9C26E6A-23BF-426D-86E4-0930B76CFC10Q86275820-9155DB57-525D-469E-8763-7D98B1912ED2Q87304637-AD1A653A-2E0E-4AA2-BB4A-9DC82748524EQ88918124-E2307926-7F3F-4DB7-877C-CCED9C2FAE17Q90632364-22EBDE69-4CA9-4FA1-9F69-20A977E8A2A7Q91545631-DCFA2DD7-59ED-49E4-BA86-CB557BE02A3EQ92481210-9EE48445-DAA3-44E7-ABC5-36E911503D5D
P50
description
researcher
@en
name
A Navarro Ruiz
@en
A Navarro Ruiz
@nl
type
label
A Navarro Ruiz
@en
A Navarro Ruiz
@nl
prefLabel
A Navarro Ruiz
@en
A Navarro Ruiz
@nl
P108
P106
P31
P496
0000-0001-7009-280X